1Barater DC. Pharmacology of diuretic. Am J Med Sci ,2000,319:38-50.
2Kurtz TW. Chlorthalidone : dont call it "thiazide-like" anymore. Hypertension,2010,56:335-337.
3Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first line agent s: a network meta analysis. JAMA,2003 ,289 :2534-2544.
4Staessen A, Wang JG, Thijs L, et al. Cardiovascular prevention and blood pressure reduction:a quantitative overview updated until 1 March 2003. J Hypertens ,2003,21 : 1055-1076.
5Black HR, Davis B, Barzilay J, et al. Metabolic an d clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hyperten- sion:a report from the antihypertensive and lipid lowering treatment to prevent heart attack trial ( ALLHAT ). Diabetes Care, 2008, 31 : 353 -360.
6Einhorn PT, Davis BR, Massie BM, et al. ALLHAT collaborative research group, the antihypertensive and lipid-lowering treatment to prevent heart attack trial ( ALLHAT ) heart failure validation study:diag- nosis and prognosis. Am Heart J,2007,153:42-53.
7Arima H, TzourioC, Butcherk, et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS Trial. Stroke,2006,37:1497- 1502.
8Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes : the NESTOR Study. J Hypertens,2004,22 : 1613-1622.
9Dahl6f B, Sever PS, Pouher NR, et al. Prevention of cardiovascular e- vents with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Ann ( ASCOT-BPLA ) : a muhicentre randomized controlled trial. Lancet, 2005,366 : 895 -906.
10Jamerson KA,Bakri s GL,Wun C C,et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension ( ACCOMPLISH ) trial: the first randomized controlled trial to compare the clinical outcome effects of firstline combination therapies in hypertension. Am J Hypertens, 2004,17 : 703-801.
